| [1] |
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, et al. The Global burden of cancer 2013[J]. JAMA Oncol, 2015,1(4):505-527. DOI: 10.1001/jamaoncol.2015.0735.
doi:10.1001/jamaoncol.2015.0735pmid:26181261 |
| [2] |
Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015,136(8):1921-1930. DOI: 10.1002/ijc.29227.
doi:10.1002/ijc.29227 |
| [3] |
Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metasta-tic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study[J]. JAMA Oncol, 2019,5(4):546-550. DOI: 10.1001/jamaoncol.2018.5441.
doi:10.1001/jamaoncol.2018.5441 |
| [4] |
Ji Z, Peng Z, Gong J. et al. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system[J]. BMC Can-cer, 2019,19(1):705. DOI: 10.1186/s12885-019-5921-9.
doi:10.1186/s12885-019-5921-9 |
| [5] |
Galluzzi L, Zitvogel L, Kroemer G. Immunological mechanisms underneath the efficacy of cancer therapy[J]. Cancer Immunol Res, 2016,4(11):895-902. DOI: 10.1158/2326-6066.CIR-16-0197.
doi:10.1158/2326-6066.CIR-16-0197pmid:27803050 |
| [6] |
Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with acce-lerated growth rate[J]. Clin Cancer Res, 2017,23(15):4242-4250. DOI: 10.1158/1078-0432.CCR-16-3133.
doi:10.1158/1078-0432.CCR-16-3133 |
| [7] |
Lo Russo G, Moro M, Sommariva M, et al. Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade[J]. Clin Cancer Res, 2019,25(3):989-999. DOI: 10.1158/1078-0432.CCR-18-1390.
doi:10.1158/1078-0432.CCR-18-1390 |
| [8] |
Greally M, Chou JF, Chatila WK, et al. Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer[J]. Clin Cancer Res, 2019,25(20):6160-6169. DOI: 10.1158/1078-0432.CCR-18-3603.
doi:10.1158/1078-0432.CCR-18-3603pmid:31337644 |
| [9] |
Kamada T, Togashi Y, Tay C, et al. PD-1+regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer[J]. Proc Natl Acad Sci U S A, 2019,116(20):9999-10008. DOI: 10.1158/1078-0432.CCR-18-3603.
doi:10.1158/1078-0432.CCR-18-3603 |
